Summary In a blind study, 518 serum samples were assayed for serum levels of mammary serum antigen (MSA) by an enzyme immunoassay (EIA) using the 3E1.2 monoclonal antibody. Using 300 IU as the arbitrary cut off to distinguish normal from abnormal individuals, 75% of patients with primary Stage I carcinoma of the breast (n = 12), 89% (Stacker et al., 1987) .
Previously we have reported the production of a monoclonal antibody 3E1.2, raised against a fresh primary carcinoma of the breast (Stacker et al., 1985a) . Immunoperoxidase staining has shown that the breast tumour-associated antigen defined by the monoclonal antibody is present on >90% of breast cancers, and to a lesser extent on normal breast epithelium and other normal tissues (Stacker et al., 1985a) . 3E1.2 also detects molecules present in human serum; a high molecular weight glycoprotein which we have called mammary serum antigen (MSA) . A competitive enzyme immunoassay was developed to quantify the level of circulating MSA in serum. MSA has been found to be elevated in patients with localised and advanced breast cancer compared to normal individuals (Stacker et al., 1985b) . In addition, changes in MSA levels have been shown to correlate with the clinical course in patients with advanced breast cancer (Stacker et al., 1987) .
Other workers have produced monoclonal antibodies which define high molecular weight glycoproteins in the serum of patients with breast cancer (Hayes et al., 1985; Papasidero et al., 1984; Burchell et al., 1984; lacobelli et al., 1986) . 3E1.2 can be distinguished from these monoclonal antibodies by its lack of reactivity with high molecular weight glycoproteins in human milk and milk fat globule membranes (Stacker et al., 1987) . In this paper we describe the MSA levels found in three separate panels of coded serum samples. Included in this study are: (i) the evaluation of MSA levels in non-breast cancers and non-malignant disorders; (ii) the use of MSA levels for monitoring the clinical course of disease in patients with breast cancer; and (iii) the comparison of MSA and CEA levels in the serum of patients with breast cancer and other diseases. (Panel C) Serum was also obtained from 19 patients undergoing treatment for breast cancer at the Cancer Institute, Melbourne and tested at the Research Centre for Cancer and Transplantation. Samples were collected twice from each patient, over an interval of two months to two years. These patients were clinically assessed at the time of the second bleed and classified as having disease that progressed (8 patients), stabilised (5 patients) or regressed (6 patients) by accepted criteria (Beahrs & Myers, 1983) . A 50% change in the original MSA level was considered significant.
Materials and methods
Serum samples were obtained from clotted blood and stored at -20°C until use. Samples from Hoffman-La Roche were transported in dry ice to Australia, and no thawing was evident on arrival. The criteria for staging and disease status is in accord with accepted definitions (Beahrs & Myers, 1983) . Samples were obtained coded, and the code not broken until the completion of testing.
Monoclonal antibody
The murine monoclonal antibody 3E1.2 was raised against fresh human carcinoma of the breast using standard somatic cell hybridisation techniques (Stacker et al., 1985a 
Assays
Serum MSA levels were determined by a competitive EIA (Stacker et al., 1987) with the variation that an avidin-biotin system (Amersham International, UK) was used to develop the assay. A cut-off level of 300 inhibition units (IU) was used for the MSA assay as it is the mean + 2 standard deviations of the level found in normal females by a previous study (Stacker et al., 1987 Figure 1 ). In general the serum MSA level in this group was low, with a median MSA level of 94 IU for nonsmokers and 104IU for smokers, although 2/30 individuals had MSA levels >300 IU being the value selected to distinguish normal from abnormal individuals. These two normal individuals, with MSA levels >300 IU, were both smokers and had serum levels of 311 and 468 IU, their respective CEA levels were 2.5ngml-1, the upper limit of normal, and 1.8ngml-1. None of the normal sera examined had raised CEA levels (Table I) . Pregnant women (30) were also examined and found to have a median MSA level 76 IU, with 4 (13%) having elevated MSA levels (315, 356, 359 and 588 IU), however, CEA levels were not raised in any of these (range 1.1-1.3 ng ml-1) ( Table I) .
Breast cancer In contrast to normal individuals, serum MSA levels were elevated in the majority of patients with active breast cancer (Table I) . Of 21 patients with localised breast cancer (stages I and II) 81% (17) had levels >300IU, with median levels of 653IU and 764IU respectively. The majority of patients (88-100%) with metastatic disease had raised levels of MSA; these consisted of 92% with bone metastases (n=25), 100% with liver metastases (n=6), 100% with lung/pleural metastases (n = 10) and 88% of patients with multiple metastases (n=-16) ( Table I Figure 1 ). CEA was found to be a poorer marker for breast cancer than MSA (Table I) . Elevated levels of CEA (>2.5ngml-1)
were found in fewer patients, in particular those with (Table I , Figure 3a) . Only 3 patients with active breast cancer had CEA levels >2.5ngmml1 but normal MSA levels (Figure 3a, b) . Whereas MSA levels were >300 IU in 40 cases with normal CEA levels (Figure 3a, b) .
No correlation was observed between CEA and MSA levels in patients with localised ( Figure 3a) or advanced breast cancer (Figure 3b ). Non-breast tumours MSA levels were determined in patients (n= 100) with 4 non-breast epithelial tumours (Table II , Figure 1 ). Of 20 patients with ovarian cancer 14 (70%) had levels >300 IU (median 598 IU). MSA was also elevated in tumours of the colon (60%), lung (71%), and kidney (59%), but in general the median level was lower (Table II) . Elevated levels of CEA were also found in this group, in particular 60% of patients with colon cancer (n = 30) and 67% of patients with lung cancer (n = 30) had levels >2.5 ng ml-1. Raised levels of CEA were also detected in 100 1000
CEA (ng ml-1) Figure 3 Correlation between MSA and CEA serum levels. (a) Figure 4) . MSA was most frequently raised in patients with disorders of the liver or gastrointestinal system (Table III, Figure 4 ). Levels >300 IU were seen in patients with hepatitis (57%), cirrhosis (62%), pancreatic disorders (43%) and gastrointestinal disorders (30%). Median levels of MSA in non-malignant diseases were in general low, exceptions being the groups of patients with hepatitis (306IU), and cirrhosis (657IU). As expected, raised levels of CEA were seen in non-malignant conditions of the lung, liver and gastrointestinal system (Table III) (Table IV) . In total, 20% (3/15) had levels of MSA >300IU. All of these patients had carcinoma of the lung with individual levels of 9915, 9758 and 988IU (Table IV, Figure 5 ). 
Discussion
This study has used a previously described competitive enzyme immunoassay (Stacker et al., 1987) to evaluate levels of MSA in the serum of normal individuals, patients with malignant tumours and non-malignant diseases. The serum analysed constituted three panels of coded samples, which were tested blindly for MSA and for CEA. Although CEA is not an ideal marker for breast cancer, its levels in serum have been well established by previous workers (Steward et al., 1974; Martin et al., 1976) and in this study serves as a useful standard for comparing MSA to other serum markers. 'Includes acute and chronic hepatitis; bIncludes hepatic and biliary cirrhosis; cIncludes chronic bronchitis; dIncludes diverticulosis, gastritis, colitis, duodenal ulcers and polyposis coli; 'Includes diarrhoea, myopathy, diabetes, fever, dermatomyositis, anaemia, mycosis fungoidis; fIncludes acute and chronic pancreatitis; "Includes polyneuritis, Hashimoto's disease, kidney transplant, pericarditis, thyroiditis, papilloma of the bladder, herpes zoster. aConsists of hepatitis (6) In general the serum MSA levels obtained in this study agree with previous observations which find it elevated in patients with localised and advanced breast cancer (Stacker et al., 1987) . The number of patients with raised levels and average level of MSA, was also found to be similar to that previously reported. A number of findings, however, did arise from this study, that were not evident from the initial work. For instance, smoking was found to cause increased levels of MSA in normal individuals; this has also been reported for other serum markers of breast cancer (Stevens & Mackay, 1973) . This result could explain the number of normal individuals with levels >300IU in the initial study (46/2400 blood donors), which on subsequent examination had no clinical evidence of breast cancer or other disease Figure 6 Changes in MSA levels with the clinical course of breast cancer. Graph showing the change in MSA values over a 2-year period in a series of breast cancer patients undergoing therapy. The patients have been classified into 3 groups according to clinical status of disease (see text for details) which had either progressed, stabilised or regressed. (Stacker et al., 1987) . Also, a number of patients with nonmalignant diseases had raised MSA levels. In particular, conditions affecting the liver, pancreas and gastrointestinal system produced elevated levels, however, in general the levels were much lower than those found in active breast cancer. Similar results have been found with other breast cancer markers (Khoo & Mackay, 1973; Hayes et al., 1985) . MSA levels were also raised in a substantial number of patients with non-breast tumours; this is not a surprising result given the tissue distribution of the monoclonal antibody 3E1.2 on secretory epithelium (Stacker et al., 1985a) . Levels (Table I) ; this has also been reported for the marker DF3 (Hayes et al., 1985) . Results of this study have also confirmed that MSA levels would be useful for monitoring the clinical course of breast cancer. Of 19 patients with metastatic breast cancer, 17 (89%) had changing levels of MSA which correlated with either progression, regression or stabilisation of disease. These results are similar to a previous study (Stacker et al., 1987) which showed a correlation in 34 (92%) breast cancer patients. This compares favourably with other studies which have shown the markers MAM-6, CEA and CA15-3 to correlate in 79%, 42% and 74% of cases respectively (Hilkens et al., 1987; Hayes et al., 1986) .
Comparison of serum levels of MSA and CEA have shown the former to be a better marker for breast cancer. MSA was clearly elevated in more patients with breast cancer than CEA, using the cut off levels of 300 IU and 2.5 ng ml-I respectively (Table I ). Substantial differences were evident, particularly in patients anticipated to have low volumes of tumour, i.e., breast cancer stage I and II, local recurrence and no clinical evidence of disease (NED). In addition, some patients with metastases also had raised MSA levels but normal CEA levels. The additive effect of MSA and CEA was only marginally better than for MSA alone, as only three patients with active breast cancer had raised CEA levels but low MSA levels. Also, no correlation could be found between CEA and MSA in either patients with breast cancer or non-breast tumours. It should be noted however, that recent studies have shown that the level of another high molecular weight serum marker for breast cancer, MAM-6, correlates with CEA (Hilkens et al., 1987) . The relevance of this finding in distinguishing between MSA and MAM-6 is unclear.
In summary, the results of this study show that levels of the tumour-associated antigen MSA may be useful for the detection and monitoring of breast cancer. Furthermore, levels of MSA are more frequently raised in breast cancer than CEA, although they appear to be elevated in a similar number of patients with non-breast tumours and nonmalignant disorders. This study has also identified a number of non-malignant disorders in which MSA levels are slightly elevated, and it is important that these are taken into consideration when assessing the overall usefulness of MSA levels.
